# Phase 3 esophageal cancer trials recruiting: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 3 for esophageal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 esophageal cancer trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/esophageal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888140 | Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer | Ruijin Hospital | Phase 3 | Recruiting | Esophageal Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888140) |
| August 26, 2026 | NCT07788001 | A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal... | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green (ICG), Disease Free Survival | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788001) |
| February 24, 2026 | NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric... | AstraZeneca | Phase 3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431281) |
| February 12, 2026 | NCT07406815 | The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer, Recurrent Laryngeal Nerve, ICG (Indocyanine Green), Lymph Node Dissection | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406815) |
| January 12, 2026 | NCT07332221 | Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial | Henan Cancer Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer | 435 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332221) |
| December 24, 2025 | NCT07303231 | The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303231) |
| October 16, 2025 | NCT07217704 | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | SOFIE | Phase 3 | Recruiting | Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217704) |
| October 7, 2025 | NCT07211009 | Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial | Sichuan University | Phase 3 | Not yet recruiting | Esophageal Cancer (EsC) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211009) |
| September 17, 2025 | NCT07177794 | Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC | Sun Yat-sen University | Phase 3 | Recruiting | Esophageal Cancer, Chemoradiotherapy | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177794) |
| May 9, 2025 | NCT06964568 | CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC | Fudan University | Phase 3 | Recruiting | Esophageal Carcinoma, Radiotherapy, Immunotherapy | 452 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06964568) |
| April 6, 2025 | NCT06914011 | Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma | Asan Medical Center | Phase 3 | Not yet recruiting | Esophageal Cancer | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06914011) |
| November 6, 2024 | NCT06676449 | TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC | Fudan University | Phase 3 | Recruiting | Esophageal Carcinoma, Radiotherapy, Immunotherapy | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06676449) |
| July 15, 2024 | NCT06501664 | Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Esophageal Cancer | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06501664) |
| April 1, 2024 | NCT06339060 | An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3). | Ruijin Hospital | Phase 3 | Recruiting | Esophageal Cancer | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06339060) |
| November 3, 2023 | NCT06115629 | Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial | University of Dublin, Trinity College | Phase 3 | Not yet recruiting | Esophageal Cancer, Gastric Cancer | 952 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06115629) |
| October 17, 2023 | NCT06086457 | PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Recruiting | Esophageal Neoplasms | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06086457) |
| May 19, 2023 | NCT05865743 | Perioperative SDD to Prevent Infectious Complications After Esophagectomy | Radboud University Medical Center | Phase 3 | Recruiting | Esophageal Cancer | 854 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05865743) |
| September 21, 2022 | NCT05547529 | The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell... | Blokhin's Russian Cancer Research Center | Phase 3 | Recruiting | Esophageal Cancer | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05547529) |
| May 3, 2022 | NCT05357846 | PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) | Sun Yat-sen University | Phase 3 | Recruiting | Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer | 422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05357846) |
| January 12, 2022 | NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 3 | Recruiting | Esophageal Cancer, Esophageal Adenocarcinoma | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05188313) |
| September 24, 2021 | NCT05055648 | PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy | University of Aarhus | Phase 3 | Recruiting | Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05055648) |
| May 4, 2021 | NCT04871412 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Lung Cancer, Gastric Cancer, Esophageal Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04871412) |
| March 30, 2021 | NCT04821843 | Neoadjuvant Treatment Modalities in Esophageal Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Recruiting | Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric... | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04821843) |
| March 30, 2021 | NCT04821778 | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Recruiting | Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04821778) |
| August 14, 2020 | NCT04513808 | Total Intravenous Anesthesia and Recurrence Free Survival | The Cleveland Clinic | Phase 3 | Recruiting | Esophageal Cancer | 1,614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04513808) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fujian Medical University Union Hospital | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 |
| Henan Cancer Hospital | 2 |
| Sun Yat-sen University | 2 |
| Fudan University | 2 |
| Ruijin Hospital | 2 |
| Sichuan University | 1 |
| Ottawa Hospital Research Institute | 1 |
| Chinese Academy of Medical Sciences | 1 |
| The Cleveland Clinic | 1 |
| University of Dublin, Trinity College | 1 |
| [Sunshine Lake Pharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-lake-pharma-co-ltd) | 1 |
| Asan Medical Center | 1 |
| Radboud University Medical Center | 1 |
| SOFIE | 1 |
| Shanghai Chest Hospital | 1 |
| Blokhin's Russian Cancer Research Center | 1 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| University of Aarhus | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 18 |
| Netherlands | 4 |
| Germany | 3 |
| Italy | 3 |
| Belgium | 3 |
| Canada | 2 |
| United States | 2 |
| France | 2 |
| United Kingdom | 2 |
| Ireland | 1 |
| Norway | 1 |
| Sweden | 1 |
| Russia | 1 |
| Australia | 1 |
| Austria | 1 |
| Brazil | 1 |
| Hungary | 1 |
| India | 1 |
| Japan | 1 |
| Malaysia | 1 |
| Poland | 1 |
| Puerto Rico | 1 |
| South Korea | 1 |
| Spain | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Cardiothoracic surgery practices in the United States](https://specstream.ai/data/businesses/cardiothoracic-surgery-practices/united-states)
- [B2B background check companies in the United States](https://specstream.ai/data/businesses/b2b-background-check-companies/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Social media agencies in the United States](https://specstream.ai/data/businesses/social-media-agencies/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
